KLK3 and posterior cortical atrophy: DCA confirmed clinical net benefit across a wide range of risk thresholds.<h4>Conclusion</h4>This nomogram provides a non-invasive, cost-effective, individualized PCa risk assessment tool for Chinese patients with elevated PSA levels.